<DOC>
	<DOCNO>NCT00257023</DOCNO>
	<brief_summary>The purpose study assess safety , effectiveness , plasma concentration paliperidone ( antipsychotic medication ) give daily treatment patient schizophrenia</brief_summary>
	<brief_title>An Exploratory Study Safety Effectiveness Paliperidone Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone extended-release tablet . Paliperidone active metabolite risperidone , approve treatment schizophrenia Japan . This multicenter , open-label , parallel-group , fix dose study evaluate safety , effectiveness , plasma concentration paliperidone take daily patient schizophrenia . The patient receive fix dose paliperidone ( 3 , 9 , 15 mg ) 6 week effectiveness safety observe additional 2 weeks.. Efficacy measure determine change throughout study Positive Negative Syndrome Scale ( PANSS ) score , scale measurement symptom schizophrenia , Clinical Global Impression ( CGI ) score . In addition , study also assess relationship dose/plasma drug concentration dopamine D2 receptor occupancy patient consent receive positron emission tomography ( PET ) . Safety evaluation ( symptom , physical exam , electrocardiogram , laboratory test , Drug-Induced Extrapyramidal Symptoms Scale [ DIESS ] result , adverse event monitoring ) conduct throughout study . The study hypothesis paliperidone effective treatment schizophrenia , well-tolerated . The patient receive either 3 , 9 , 15 mg paliperidone , take daily mouth 6 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients diagnose schizophrenia accord diagnostic criterion DSMIV take one oral antipsychotic medication within 28 day study entry score 120 pretreatment Positive Negative Syndrome Scale Score ( PANSS ) , scale measurement symptom schizophrenia Diagnosis psychiatric disease schizophrenia accord diagnostic criterion DSMIV history Parkinson 's disease , seizure disorder , cerebrovascular accident , diabetes mellitus , clinically significant gastrointestinal disorder , severe impairment liver kidney drug allergy hypersensitivity antipsychotic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Positive Negative Syndrome Scale ( PANSS )</keyword>
	<keyword>Clinical Global Impression ( CGI )</keyword>
	<keyword>Positron Emission Tomography ( PET )</keyword>
</DOC>